This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): gemtuzumab ozogamicin for injection
Description: Mylotarg is the pioneering antibody-drug conjugate and combines an antibody against CD33 conjugated to calicheamicin. The CD33 antigen is expressed by hematopoietic cells, and binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
Deal Structure: Celltech entered into a collaboration with Wyeth in 1991 for the research, development and commercialization of antibody cytotoxic conjugates as novel oncology treatments. Mylotarg arose out of this collaboration. Under the terms of the collaboration, Wyeth is responsible for clinical development and funds the majority of trial costs for CMC-544. Celltech contributes a portion of clinical development costs. Celltech will receive royalties on world-wide sales of any products that are successfully commercialized. In 2004, UCB acquired Celltech.
Due to PDL's humanization patents, PDL is entitled to receive a flat-rate royalty based upon Wyeth's net sales of Mylotarg.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
In June 2012, Takeda and...See full deal structure in Biomedtracker
Partners: UCB SA PDL BioPharma, Inc.
Additional information available to subscribers only: